Cargando…
Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients – an immunohistochemical study
INTRODUCTION: Diffuse large B-cell non- Hodgkin lymphoma (DLBCL) is the largest common category of adult lymphoma. Recurrence and treatment resistance occurs in one-third of cases, triggering them to the progressive stage of DLBCL after treatment. Detection of novel predictive and prognostic biomark...
Autores principales: | Mohamed, Asmaa Hussein, Elfeky, Mariem A., Elshorbagy, Shereen, Hefzi, Nabila, Oraby, Tamer, Abdelhady, Waleed A., Eldein, Mahmoud Sharaf, Embaby, Ahmed, Oraby, Ehab M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052345/ https://www.ncbi.nlm.nih.gov/pubmed/35506035 http://dx.doi.org/10.5114/wo.2022.115675 |
Ejemplares similares
-
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
por: Munshi, Manit, et al.
Publicado: (2020) -
MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity
por: Saikh, Kamal U.
Publicado: (2021) -
Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88‐Dependent Inflammation
por: Luo, Wu, et al.
Publicado: (2022) -
Identification and Function of Myeloid Differentiation Factor 88 (MyD88) in Litopenaeus vannamei
por: Zhang, Shuang, et al.
Publicado: (2012) -
A MyD88 meddles with survival
por: Bashyam, Hema
Publicado: (2007)